Buradasınız

Anasayfa » Content

BOTULINUM TOKSİN İ (BTX ) VE KLİNİK KULLANIMI

BOTULINUM TOXIN (BTX ) AND CLINICAL USAGE

Journal Name:

  • İstanbul Üniversitesi Diş Hekimliği Fakültesi Dergisi

Publication Year:

  • 2004

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Botulinum Toxin (BTX ), has been used medically since the last 25 years. The toxin derived from the Clostridium botulmum, manifests its temporary paralytic effects which provide chemical denervation by inhibiting the release of acetylcholine at neuro-muscular junction. At present, BTX applications have become an alternate to surgery i it esthetic and therapeutic purposes and its practical uses has increased in oral surgery as well as with plastic surgery. Mainly the masseter hypertrophy and also the other muscle masticatory muscle hypertrophies and hyperactivities, oromandihular-facial-lingual dystonia, recurrent TMJ dislocations due to the muscle coordination damage developing secondary due to these dystonias, bruxism, esthetic rehabilitation of mimic muscles problems developed after surgery and the other cosmetic rehabilitations with or without collagen, spasms, tics, malfunctions with salivary glands (hypersalivation, Frcy syndrome ), in the control of myofacial pain and other pain, paralysing geniohyoid muscle under the EMG control to prevent relapses in pcrfonning mandibular advancement by surgery are the most common uses of BTX in maxillofacial surgery. In this article, the uses of BTX in maxillofacal surgery, its structure, side effects and issues taken into account in its usage arc evaluated.
Bookmark/Search this post with
Abstract (Original Language): 
Botulinum toksini (BTX), son 25 yıldır tıbbi kullanım alanı bulmuştur. Clostridium botulmum 'dan elde edilen bu toksin, kimyasal geçici paralitik etkilerini nöromüsküler kavşakta asetİlkoiin şahmınım önleyerek gösterir. Günümüzde BTX uygulamaları estetik veya tedavi amacıyla cerrahiye alternatif olmakta, plastik cerrahinin yanı sıra oral cerrahi alanında da pratik kullanımı giderek artmaktadır. Başta masseter kas hipertrofîsi olmak üzere çiğneyici kas hipertrofileri ve hiperaktivitelerİ, oromandibular-fasİyal-lingual distotüter ve bunlara sekonder olarak bozulan kas koordinasyonu nedeni ile tekrarlayan temporomandibuler eklem (TME) dislokasyonları, bruksizm, cerrahi sonrası gelişen mimik kaslarla ilgili problemlerin estetik düzeltilmesi ve tek başına veya kollagen ile diğer kozmetik düzeltmeler, kas spazmları, tikler, tükürük bezleri ile İlgili mal fonksiyonlar (hipersalivasyon, Frey sendromu), myofasiyal ağrı ve diğer ağrı kontrollerinde, mandibulanın öne alındığı cerrahi operasyonlarda relapsı önlemek için EMG kontrollü geniohyoid kasın paralizisi, BTX'un maksillofasiyal cerrahideki başlıca kullanım alanlarıdır. Bu makalede BTX'un maksillofasiyal cerrahide kullanım alanları, yapısı, etki mekanizması, yan etkileri ve kullanımda dikkat edilecek konular değerlendirilmiştir.
FULL TEXT (PDF): 
PDF icon arastirmax-botulinum-toksin-i-btx-klinik-kullanimi.pdf
  • 3-4
37
43
  • Turkish

REFERENCES

References: 

1- Kimura K, Kimura H, YokosawaN, Isogai H, Isogaİ E, Kozaki S, Miyamoto A, Nishikawa T, Ohshika H, Kubota T, Fuji N. Negative chronotropic effect of botulinum toxin on neonatal rat cardiac myocytes. Biochem Biophys Res Commun, 1998: 244; 275-279.
2- Cichon JV, McCaffrey TV, Litchy WJ, Knops JL. The effect of botulinum toxin type A injection on compound muscle action potential in an İn vivo rat model. Laryngoscope, 1995: 105: 144-148.
3- Niamtu JB. Botulinum toxin A: a review of 1085 oral and maxi 1 lofacial patient treatments. J Oral Maxillofac Surg, 2003: 61: 317-324.
4- Jankovic J. Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med, 1991: 324: 1186-1194.
5- Aoki R. The development of BOTOX -Its history and pharmacology. Pain Digest, 1998: 337-341.
6- van Em en gem E. Ueber einem neuen anaeroben bacillus und seine Beziehungen zum botulismus. Z H Infectionskrankh 1897: 26: 1-56. (English translation, Rev Infect Dis, 1979: 1: 701-719) (4. kaynaktan nakledilmiştir).
7- Atassİ Z, Dressier D, Jankovic J, Blazer J. Justinus Kerner and the history of botulism The latest news in sience and therapeutics. Newsletter of Internationale cortfeiance 2002: Hannover, Germany.
8- Scott AB. Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophtalmol Soc, 1981: 79: 734-370.
9- Heise GJ, Mullen MP. Oromandibular dystonia treated with botulinum toxin: Report of case. J Oral Maxillofac Surg, 1995: 53: 332-335.
10- Niamtu J. Aesthetic uses of botulinum toxin A. J Oral Maxillofac Surg, 1999: 57: 1228¬1233.
11- To EWH, Ahuja A, Ho WS, King WWK, Parg PCW, Hut ACF. A prospective study of the effect of botulinum toxin A on masseteric muscle hypertrophy with ultrasonographic
and electromyographic measurement. British Journal of Plast Surgery, 2001: 54: 197-200.
12- White CM, Greensmith L, Vrbova G. Repeated stimuli for axonal growth causes motoneuron death in adult rats: the effect of botulinum toxin followed by partial denervation. Neuroscience 2000, 95: 1 101-9.
13- Herreros J, Marti E, Rtii?,-Montasell B, Casanova A, Niemann H, Blasi J. Localization of putative receptors for tetanus toxin and botulinum neurotoxin type A in rat central nervous system. Eur J Neurosci, 1997: 9: 2677-2686.
14- Inagi K, Rodriquez AA, Ford CN, Heisey DM. Transoral electromyographic recordings in botulinum toxin-injected rat larynges. Ann Otol Rhinol Laryngol, 1997: 106: 956-964.
15- Lu L, Atchabahİan A, Mackİnnon SE, Hunter DA. Nerve injection injury with botulinum toxin. Plast Reconstr Surg, 1998: 101: 1875¬1880.
16- Freund BJ, Schwartz M. Relief of tension-type headache symptoms in subjects with temporomandibular disorders treated with botulinum toxin-A. Headache, 2002: 42: 1033-1037.
17- Aoki RK. Preclinical update of BOTOX (botulinum toxin type -A) purufied neurotoxin complex relative to other botulinum toxin preparations. Eur J Neurology, 1999: 6: 3-10.
18- Munchau A, Bhatia KP. Uses of botulinum toxin injection in medicine today. Clinical review. British Medical Journal, 2000: 320: 161-165.
19- Tan EEC, Jankovic J. Treating severe bruxism with botulinum toxin. J Am Dent Assoc, 2000: 131:211-216.
20- Quinn N, Hallet M. Dose standardisation of botulinum toxin. The Lancet, 1989: 1: 964.
21- Schantz EJ, Jonson EA. Dose standardisation of botulinum toxin. The Lancet, 1990: 335¬421.
22- Mandel L, Tharakan M. Treatment of unilateral masseteric hypertrophy with botulinum toxin: Case report. J Oral Maxillofac Surg, 1999: 57: 1017- 1019.
23- Borodİc GE, Acquadro MA. The use of botulinum toxin for the treatment of chronic facial pain. Journal of Pain, 2002: 3: 21-27.
24- Smyth AG. Botulinum toxin treatment of bilateral masseteric hypertrophy. Br J Oral Maxillofac Surg, 1994: 32: 29-33.
25- Freund B, Schwartz M, Symington JM. Botulinum toxin: new treatment for temporomandibular disorders. Br J Oral and Maxillofacial Surgery, 2000: 38: 466-471.
Botulinum
Toksin
i (BTX) ve Klinik Kullanımı
26- Freund BJ, Schwartz M. Intramuscular injections of botulinum toxin as an adjunct to arthrocentesis of the temporomandibular joint: preliminary observations. British Journal of Oral and Maxillofac Surg, 2003: 41: 351-352.
27- Chikhani L, Dİchamp J. Bruxisme, temporomandibular dysfunction and botulinum toxin. Annales de readaptation et de medecine physique, 2003: 46: 333-337.
28- Beerens AJ, Snow GB. Botulinum Toxin A in the treatment of patients with Frey sydrome: BrJSurg, 2002: 89: 116-119.
29- Umstadt HE. Botulinum Toxin in maxillofacial surgery. Mund Keifer Gesictschir, 2002: 6: 249-260.
30- Brin MF, Blitzer A, Steward C. Laryengeal dystonia (spasmodic dysfonia): observations of 901 patients and treatment with botilinum toxin In: Fahn S, Marsden CD, DeLong DL. Advanges in neurology. Dystonia. Philadelphia: Lippincot , Raven, 1998: 237¬252.
31- Jitpimolmard S, TİamkaoS, Laopaiboon M. Long term results of botulinum toxin type A (Dysport) in the treatment of hemifacial spasm. J Neurol Neurosurg Psychiatry, 1998: 64: 751-757.
32- Tsui JKC, Eisen A, Stoeddl AJ, CalneS. Double bind study of botulinum toxin in spasmodic torticollis. Lancet, 1986: 2: 245¬247.
33- Freund B, Schwartz M. Temporal relationship of muscle wekness and pain reduction in subjects treated with botulinum toxin A. The Journal of Pain, 2003, 4: 159-165.
34- Nixdorf DR, Heo G, Major PW. Randomized controlled trial of botulinum toxin A for chronic myogenous orofacial pain. Pain, 2002: 99: 465-473.
35- Saper JR. Botulinum toxin and chronic facial pain. Journal of Pain, 2002: 3: 21-27.
36- von Lİndem JJ, Niederhagen B, Beige S, Appel T. Type A botulinum toxin in the treatment of chronic facial pain associated with masticatory hyperactivity. J Oral Maxillofac Surg, 2003: 61: 774-778.
37- Dencer D. Bilateral idiopathic masseter hypertrophy. Br J Plast Surg, 1961: 14: 149 (36. kaynaktan nakledilmiştir).
38- Legg JW. Enlargement of temporal and masseter muscles on both sides. Trans Pathol
43
Soc Lond 1880, 31: 361-366 (36. kaynaktan nakledilmiştir)
39- Fİlippİ GM, Errico P, Santarelli R, Bagolinİ B, Manni E. Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol, İ993: 113:400-404.
40- Moore AP, Wood GD. The medical management of masseteric hypertrophy with botulinum toxin type A. Br J Oral Maxillofac Surg, 1994: 32: 26-28.
41- Gurney CE. Chronic bilateral benign hypertrophy of the masseter muscles. Am J Surg, 1947: 74: 137-139.
42- Hata T, Hosoda M.Unilateral temporalis muscle hypertrophy managed with botulinum toxin type A. British journal of Oral and Maxillofacial Surgery, 2000: 38: 571-574.
43- von Lindern JJ, Niederhagen B, Appel T, Berge S, Reiçh RH. Type A botulinum toxin for the tretment of hypertrophy of the masseter and temporal muscles: An alternative treatment. Plastic and Reconstructive Surgery, 2001: 107: 327-332.
44- Hui ACF. Botulinum toxin for treatment of masseteric hypertrophy. J Neurol, 2002: 249¬345.
45- Kİm HJ, Yum K-W, Lee S-S, Heo M-S, Seo K. Effects of botulinum toxin type A on bilateral masseteric hypertrophy evaluated with computed tomographic measurement. Dermatol Surg, 2003: 29: 484-489.
46- Shore NA. Temporomandibular joint dysfunction and occlusal equilibration. 2nd ed. Philadelphia: J.B. Lippincott, 1976: 60-61.
47- Daelen B, Thorwirth V, Koch A. Treatment of recurrent dislocation of the temporomandibular joint with type A botulinum toxin. Int J Oral Maxillofac Surg, 1997: 26: 458- 460.
48- Pidcock FS, Wise JM, Christensen JR. Treatment of severe post-traumatic bruxism with botulinum toxin-A : Case report. J Oral Maxillofac Surg, 2002: 60: 115-117.
49- Mendez-Eastman SK. Botox: A review. Plastic Surgical Nursing, 2000: 20: 60-65.
50- Blazer J, Zouhair A, Dresser D, Jancovic J. Botulinum toxin update: The latest news in sience and therapeutics. Newsletter of Internationale Conferance, 2002: Hannover, Germany.

Thank you for copying data from http://www.arastirmax.com